Evaluation of Busulfan as a Third-Party Immunoassay on a Clinical Chemistry Analyzer
The Journal of Applied Laboratory Medicine · 2024
DOI: 10.1093/jalm/jfad134 ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift The Journal of Applied Laboratory Medicine, 2024. Verfasst von Janet R Zhou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Busulfan, Drug Monitoring. Die Arbeit nennt 17 Literaturangaben. Gefördert von: Busulfan MyCare Oncology.
Abstract (Originalsprache)
Background
Busulfan is widely used in conditioning regimens to prepare patients for hematopoietic stem cell transplantation. Therapeutic drug monitoring (TDM) is critical due to large inter- and intra-individual variability in busulfan pharmacokinetics, and the risk of adverse consequences of toxicity including hepatic veno-occlusive disease. Busulfan is most commonly measured by liquid chromatography–mass spectrometry (LC-MS/MS), which is not as widely available in clinical laboratories as automated routine clinical chemistry analyzers. The objective was to perform analytical verification of a busulfan immunoassay on the Abbott Alinity c platform.
Methods
The MyCare Oncology busulfan immunoassay was configured as a third-party reagent on the Abbott Alinity c. Imprecision, linearity, sample carryover, and onboard stability of reagent studies were evaluated. The performance of the busulfan immunoassay using the Abbott Alinity c was compared to the Beckman Coulter AU480 using sodium heparinized plasma, as well as to LC-MS/MS using lithium heparinized plasma.
Results
The imprecision goal of 8% was met, and linearity within the analytical measurement range of 240 to 1700 ng/mL was verified. Sample carryover was negligible, and the reagents were stable onboard for at least 84 days. The busulfan immunoassay correlated well with LC-MS/MS (slope = 0.949, y-intercept = −7.8 ng/mL, r2 = 0.9935) and the Beckman Coulter AU480 (slope = 1.090, y-intercept = −34.5 ng/mL, r2 = 0.9988).
Conclusions
This study demonstrated successful analytical verification of a busulfan third-party immunoassay on the Abbott Alinity c platform. The ability to perform TDM of busulfan on a routine clinical chemistry analyzer will positively impact turnaround times to improve patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
- Division of Clinical Biochemistry, University Health Network, Toronto, ON, Canada.
- Saladax Biomedical, Inc., Bethlehem, PA, United States.
- Division of Clinical Biochemistry, Department of Paediatric Laboratory Medicine, Hospital for Sick Children, Toronto, ON, Canada.
Förderung
- Busulfan MyCare Oncology
Zitieren
APA
Zhou, J. R., To, A., Fritz, J., Jung, B., Yazdanpanah, M., & Kulasingam, V. (2024). Evaluation of Busulfan as a Third-Party Immunoassay on a Clinical Chemistry Analyzer. The Journal of Applied Laboratory Medicine. https://doi.org/10.1093/jalm/jfad134
Vancouver
Zhou JR, To A, Fritz J, Jung B, Yazdanpanah M, Kulasingam V. Evaluation of Busulfan as a Third-Party Immunoassay on a Clinical Chemistry Analyzer. The Journal of Applied Laboratory Medicine. 2024. doi:10.1093/jalm/jfad134
BibTeX
@article{Zhou2024,
author = {Zhou, Janet R and To, Andrea and Fritz, James and Jung, Benjamin and Yazdanpanah, Mehrdad and Kulasingam, Vathany},
title = {Evaluation of Busulfan as a Third-Party Immunoassay on a Clinical Chemistry Analyzer},
journal = {The Journal of Applied Laboratory Medicine},
year = {2024},
doi = {10.1093/jalm/jfad134}
}
EUVIMED